Biomaterial Database

Treatment of hepatitis C in a lung transplant recipient with sofosbuvir and daclatasvir. 2016

Karen Doucette, and Suzanne Sumner, and Justin Weinkauf

Division of Infectious Diseases University of Alberta, University of Alberta, Edmonton, Alberta, Canada.

UI	MeSH Term	Description	Entries
D008297	Male		Males
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D011183	Postoperative Complications	Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.	Complication, Postoperative,Complications, Postoperative,Postoperative Complication
D012131	Respiratory Insufficiency	Failure to adequately provide oxygen to cells of the body and to remove excess carbon dioxide from them. (Stedman, 25th ed)	Acute Hypercapnic Respiratory Failure,Acute Hypoxemic Respiratory Failure,Hypercapnic Acute Respiratory Failure,Hypercapnic Respiratory Failure,Hypoxemic Acute Respiratory Failure,Hypoxemic Respiratory Failure,Respiratory Depression,Respiratory Failure,Ventilatory Depression,Depressions, Ventilatory,Failure, Hypercapnic Respiratory,Failure, Hypoxemic Respiratory,Failure, Respiratory,Hypercapnic Respiratory Failures,Hypoxemic Respiratory Failures,Respiratory Failure, Hypercapnic,Respiratory Failure, Hypoxemic,Respiratory Failures
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000998	Antiviral Agents	Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.	Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D016040	Lung Transplantation	The transference of either one or both of the lungs from one human or animal to another.	Grafting, Lung,Transplantation, Lung,Graftings, Lung,Lung Grafting,Lung Graftings,Lung Transplantations,Transplantations, Lung
D016896	Treatment Outcome	Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.	Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D019698	Hepatitis C, Chronic	INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.	Chronic Hepatitis C
D066027	Transplant Recipients	Individuals receiving tissues or organs transferred from another individual of the same or different species, or from within the same individual.	Recipient, Transplant,Recipients, Transplant,Transplant Recipient

Related Publications

Karen Doucette, and Suzanne Sumner, and Justin Weinkauf

Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C.

June 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,

Karen Doucette, and Suzanne Sumner, and Justin Weinkauf

Treatment of chronic hepatitis C viral infection with sofosbuvir and daclatasvir in kidney transplant recipients.

February 2019, Transplant infectious disease : an official journal of the Transplantation Society,

Karen Doucette, and Suzanne Sumner, and Justin Weinkauf

Safe and effective treatment with daclatasvir and asunaprevir in a liver transplant recipient with severe cholestatic hepatitis C.

December 2015, Hepatology research : the official journal of the Japan Society of Hepatology,

Karen Doucette, and Suzanne Sumner, and Justin Weinkauf

Sofosbuvir and daclatasvir in mono- and HIV-coinfected patients with recurrent hepatitis C after liver transplant.

January 2017, Annals of hepatology,

Karen Doucette, and Suzanne Sumner, and Justin Weinkauf

Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.

April 2016, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society,

Karen Doucette, and Suzanne Sumner, and Justin Weinkauf

Successful treatment of hepatitis C virus infection combining daclatasvir and simeprevir in a heart transplant recipient with decompensated cirrhosis.

July 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation,

Karen Doucette, and Suzanne Sumner, and Justin Weinkauf

Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients.

January 2020, Current drug safety,

Karen Doucette, and Suzanne Sumner, and Justin Weinkauf

Daclatasvir-Sofosbuvir for treatment of hepatitis C virus in patients with inherited bleeding disorders.

July 2017, Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology,

Karen Doucette, and Suzanne Sumner, and Justin Weinkauf

Safety and efficacy of sofosbuvir/ledipasvir and sofosbuvir/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis.

December 2021, European journal of gastroenterology & hepatology,